chr8-19962213-C-A

Variant summary

Our verdict is Uncertain significance.
+2 Uncertain · Warm
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 2 classification points (ACMG Germline Pathogenicity v2019). PVS1_ModeratePM2BP6_Moderate

The NM_000237.3(LPL):c.1421C>A (p.Ser474*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. This is a loss-of-function variant that does not trigger NMD. The variant allele was found at a cumulative frequency of 0.00000205 (AC=3) in the gnomAD database across 1,460,822 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000116. In-silico predictor (BayesDel (noAF)) classifies this variant as likely damaging/oncogenic. Variant has been reported in ClinVar as Benign/Likely Benign (★).

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

LPL
NM_000237.3 stop_gained

Scores

5
1
1

Clinical Significance

Benign criteria provided, single submitter B:1

Conservation

PhyloP100: 0.429

Publications

746 publications found
Variant links:
Genes affected
LPL (HGNC:6677): (lipoprotein lipase) LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
LPL Gene-Disease associations (from GenCC):
  • familial lipoprotein lipase deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Genomics England PanelApp, Natera, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • hyperlipidemia, familial combined, LPL related
    Inheritance: AD, SD, Unknown Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, PanelApp Australia, Natera

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000237.3, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Uncertain_significance. The variant received 2 points.

PVS1Null variant in LOF gene
Non-NMD frameshift: disease mechanism, end-terminal — moderate (PVS1 downgraded to PM); Stop-gained (exon 9 of 10) at amino acid 474 of 475; NMD not predicted. Loss of function is a known disease mechanism, though the variant is in the terminal region of the CDS.
PM2Absent/extremely low in population databases
Very rare in gnomAD for AD/XL gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.0000116 — very rare for AD+AR gene (base 0.0001, raised to 0.000356 by highest known P/LP ClinVar AF 0.000356) — PM2 moderate.
BP6Reputable source reports benign
ClinVar 1-star benign — moderate (BP6); ClinVar germline classification: Benign/Likely Benign, 1 star(s).

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000237.3. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

LPL NM_000237.3
MANE Select
HGVSc / HGVSpc.1421C>Ap.Ser474*
Exon rankExon 9 of 10
stop_gained
Prot: NP_000228.1UniProt: P06858

Ensembl Transcripts

LPL ENST00000650287.1
MANE Select
HGVSc / HGVSpc.1421C>Ap.Ser474*
Exon rankExon 9 of 10
stop_gained
Prot: ENSP00000497642.1UniProt: P06858
LPL ENST00000965928.1
HGVSc / HGVSpc.1421C>Ap.Ser474*
Exon rankExon 11 of 12
stop_gained
Prot: ENSP00000635987.1UniProt: P06858
LPL ENST00000965929.1
HGVSc / HGVSpc.1418C>Ap.Ser473*
Exon rankExon 9 of 10
stop_gained
Prot: ENSP00000635988.1UniProt: A0ACI8VCL6

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 3 sources
GnomAD3 genomes
Cov:32
GnomAD4 exome
AF: 0.00000205
AC:3
Hom:0
AN:1460822
Cov:31
GnomAD4 genome
Cov:32
Showing 3 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
SCHEMA
(Schizophrenia)
0.0000151 166408 0.00 0130382
Showing 1 cohortAllele count / allele number. AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Benign
Revision:criteria provided, single submitter
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
1
not provided (1)

Computational Scores

AlphaGenome AVI
Pathogenic62
BayesDel_addAF
Pathogenic0.56D
BayesDel_noAF
Pathogenic0.57
CADD
Pathogenic55
DANN
Uncertain1.0
Eigen
Pathogenic0.99
Eigen_PC
Pathogenic0.83
FATHMM_MKL
Benign0.72D
GPN-Star LLR
N/A-9.9
GPN-Star score
N/A9.9
PhyloP100
Benign0.43
Showing 11 of 11 scores

Splicing Scores

DS_DG_spliceai
Pathogenic0.85
Position offset: -3
Pangolin (max)
Pathogenic0.61
Pangolin gain
Pathogenic0.61
Position offset: -3
Pangolin loss
Uncertain0.24
Position offset: 6
SpliceAI score (max)
Pathogenic0.85
Details are displayed if max score is > 0.2
Showing 5 of 5 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.